Biolocity

Emory and Georgia Tech

Funding

by

Innovations Selected for Biolocity Launch

 

Five research innovations from Emory University and Georgia Tech selected for Biolocity Launch.

The Biolocity team is excited to announce the faculty-lead innovations selected to participate in the newest cohort of Biolocity Launch! In addition to receiving funding to support commercialization milestones, awardees join a year-long collaboration with consultants and business advisors for project management and longitudinal coaching to accelerate the development of their patient-impacting technologies.

Each year, Biolocity opens an intensive, multi-stage application process that provides applicants with the opportunity to receive pitch coaching, market assessments, and competitive analysis needed for commercial success. Faculty work with entrepreneur advisors to de-risk their technology at each application stage before final acceptance into the program by an oversight committee comprised of venture capitalists, entrepreneurs, clinicians, biomedical engineers, and university technology transfer experts.

Below are the select projects included in this year’s cohort:

  1. Dynamic Sampling Platform: This platform technology aims to provide simple, accurate, and low-cost quality monitoring for cell therapy bioreactors. Principal Investigators: Andrei Fedorov, PhD, Georgia Tech, Edwin Horwitz, MD, Emory University, and Mason Chilmonczyk, PhD, Georgia Tech.
  2. Focused Cryo: A cryoablation system designed to aid in targeting peripheral nerves in a highly precise manner. The platform has applications in metabolic syndromes, obesity, hypertension, diabetes, and chronic pain. Principal Investigators: David Prologo, MD, FSIR, Emory University.
  3. NanoCliq: A vaccine technology that leverages protein nanoparticle platform to prevent the onset of Leishmaniasis, a fatal disease that currently has no vaccine available. Principal Investigator: M.G. Finn, PhD, Georgia Tech.
  4. New Therapeutic for Inflammatory Bowel Disease (IBD): The development of an LRH-1 agonist drug which increases innate steroid production specifically at the site of inflammation in the gut. Principal Investigators: Nathan Jui, PhD, Emory University, Eric Ortlund, PhD, Emory University, and John Calvert, PhD, Emory University.
  5. Twice Therapeutics: A two-step method that can deliver long-lasting gene therapies to diseased tissues without re-engineering viruses. Principal Investigators: James Dahlman, PhD, Georgia Tech and Eric Sorscher, MD, Emory University

“We are fortunate in this current climate to continue to be able to provide funding that will assist the commercialization of these promising technologies,” says Manuel Kingsley, interim director of the Biolocity Program. “While research may look different this year, the passion these innovators have for improving healthcare delivery is unwavering as is our team’s commitment to their advancement. We look forward to working with each awardee to support their technology development.”

Funding and commercialization support provided by Biolocity is used to bridge the gap in development between early-stage university research and its path to the market. If you are interested in commercialization guidance for a device, therapeutic, or platform technology with the ability to positively impact human health, schedule a meeting here.

To learn more about Biolocity’s funding and partnership opportunities, visit www.Biolocity.org.

by

Biolocity 2019 RFP Release

Biolocity’s annual funding cycle is now open for the acceleration of university innovations!  Faculty in search of funding and commercialization guidance to meet strategic development milestones for commercial success are encouraged to apply.

Funds available for a broad range of technologies.

Application Details Here

 

by

Technologies Selected for Biolocity Commercialization Funding

 
Five promising biomedical research innovations across three campuses have been chosen for Biolocity’s newest cohort.

Faculty at Georgia Tech, Emory University, and Georgia State University have been selected to receive a broad range of support from Biolocity to accelerate the commercialization of their patient impacting technologies. During their funding period, each team will receive project management and work directly with business experts and consultants to de-risk their technology and advance its development. [Read more…] about Technologies Selected for Biolocity Commercialization Funding

by

Introducing Biolocity: Guiding Medical Innovation to Market

 
The Coulter Translational Fund is excited to announce its next-generation effort, Biolocity.

Biolocity stems from the expansion of a successful five year pilot in which the program awarded over $6.2 million to 40 innovative projects leading to 20 start-ups, and three products on the market. As a result of the Coulter Fund’s successful pilot and the increasing demands for translational funding and mentorship, Biolocity was created to address the need for a broader network of support for university innovators.

“Biolocity extends our successful Coulter Translational Program model to reach a larger, more diverse cohort of innovators at earlier stages of their discovery, guides them using our successful experts-in-residence process, and cultivates individualized links with the commercialization ecosystem,” said Susan Margulies, Chair of the Wallace H. Coulter Department of Biomedical Engineering.  

Similar to the Coulter program, Biolocity provides university innovators with a combination of investment, resources, and guidance that early-stage medical technologies need to reach critical commercialization milestones. We utilize three collaborative methods to advance translational science to the marketplace:

  1. BiolocityU provides educational programming in life science commercialization, trains interns on technology assessment and commercialization strategy, and offers year-round consultations opportunities to faculty innovators.
  2. Biolocity Fund features a bi-annual funding cycle for patient impacting technologies from our partner institutions. Candidates participate in a rigorous application process to identify the most compelling medical technologies to receive funding and coaching.
  3. Biolocity Launch provides awardees with active project management and coordination with the biotech commercialization ecosystem to access resources needed to achieve translational goals.

Biolocity Process Graphic

Bringing both the experience and success of the Coulter process, Biolocity creates a multi-institutional network to support the commercialization of medical technology in the southeast. The program adds new connectivity across Atlanta, while deepening its commitment to Emory University and the Georgia Institute of Technology.

“We are grateful to the Coulter Foundation’s support our pilot and proud of our teams’ successes”, said Shawna Khouri, managing director of Biolocity. “As our program evolves and continues to grow as Biolocity, we look forward to expanding our network with new partners and adding connections within the Atlanta biotech ecosystem.”

To learn more about Biolocity’s upcoming funding cycle and educational opportunities, visit www.biolocity.org.